ZANTAC
LOE ApproachingNDAORALSYRUP
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC is an oral syrup formulation approved in 1988 for gastroesophageal reflux disease (GERD). The mechanism of action and pharmacologic class are not publicly detailed in available data, but the product represents a foundational therapy in the acid-suppression market. As a small-molecule oral agent, it has established a long clinical presence in GI therapeutics.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); brand and generic teams should prepare for rapid market transition and potential workforce restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers
Started May 2009
42 enrolled
Healthy
Career Relevance
ZANTAC offers limited career growth in brand development due to mature market position and approaching loss of exclusivity. Opportunities exist in generic transition roles, managed care defense, and compliance-related functions as the market shifts to commoditized pricing.
Brand Manager
Worked on ZANTAC at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.